Glucagon-like peptide-1 receptor agonist (GLP-1RA) use among U.S. adults with type 2 diabetes (T2D) surged to 19.4% by 2022, representing 5.1 million people and quadrupling from 2016 levels1,2. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.